Single-Cell Transcriptomic Drug Repurposing in Multiple Sclerosis Cerebrospinal Fluid Identifies Novel Candidates Including IPI-145, LXR-623, and MDM2 Inhibitors

Read full text Summarise with VIRAT
Authors: Glen Charles Ritschel, Claude
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This preprint reports a computational drug repurposing pipeline applied to GSE138266, a single-cell RNA sequencing dataset comprising cerebrospinal fluid (CSF) from 6 multiple sclerosis (MS) patients and 6 IIH neurological controls (Schafflick et al., Nature Communications, 2020). Using scVI dimensionality reduction, Leiden clustering, and Wilcoxon differential expression comparing MS vs IIH globally and across T cell, B cell, monocyte, and pro-MS cluster subsets, LINCS L1000 transcriptomic reversal scoring across 26 independent Enrichr queries identified 236 NOVEL_ALL candidates (43% of assessed compounds) with no prior published association with MS, neuroinflammation, or myelin biology. Top candidates: SA-440832 (124,503), AMG-837/TRPV1 antagonist (76,398), R-547/CDK inhibitor (61,143), RG-7388/MDM2 inhibitor (60,244), SAR405838/MDM2 inhibitor (59,365), LXR-623/LXR agonist (55,577), IPI-145/duvelisib/PI3Kδγ inhibitor (52,368). IPI-145 (FDA-approved) implicates dual PI3Kδ/γ inhibition of intrathecal T/B cells and monocytes as a novel MS strategy. LXR-623 addresses both neuroinflammation and remyelination — the first transcriptomically-guided remyelination candidate from CSF scRNA-seq. MDM2 inhibitors (SAR405838, RG-7388) extend cross-disease p53-MDM2 axis consistency to three independent tissues across 10 pipelines. Code: github.com/glenritschel/ms-scrna.

Fields of Study & Subjects

Multiple Sclerosis Research Studies Computational Drug Discovery Methods Single-cell and spatial transcriptomics

Publication details

Journal / source
Zenodo (CERN European Organization for Nuclear Research)
Publication date
21 March 2026
Language
EN
Document type
Preprint